

Report of the Monitoring Agency (MA)

Name of the issuer	: Astal Laboratories Limited
For quarter ended	: Q4 FY2025-26
Name of the Monitoring Agency	: Acuite Ratings and Research Limited
(a) Deviation from the objects	: No deviation is observed.
(b) Range of Deviation	: Not applicable
(c) Any other material fact to be highlighted	: None

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

Vikas Mishra
Deputy Vice President - Process Excellence

1. Issuer Details:

Name of the issuer : Astal Laboratories Limited
Names of the promoter : Aceso Research Labs LLP
Industry/sector to which it belongs : Pharmaceuticals / Healthcare

2. Issue Details:

Issue Period : October 09, 2025, to January 14, 2026
Type of issue : Preferential Issue
Type of specified securities : Equity Shares
IPO Grading, if any : Not applicable
Issue size : INR 276.87 Cr.

3. Details of the arrangement made to ensure the monitoring of issue proceeds

Particulars	Reply from the issuer	Source of information/ certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments the Board of Directors
1. Whether all utilization is as per the disclosures in the Offer Document?	Yes	Documents provided by the Issuer, including: Private Placement Offer Cum Application Letter, Certified True Copy of Extra-ordinary General Meeting, Disclosures published on Stock Exchange, Statutory Auditor's Certificate, etc.	Yes, the private placement of equity shares was executed as per the terms mentioned in the Private Placement Offer Cum Application Letter. There is no offer document for this preferential issue.	Yes, the private placement of equity shares was executed as per the terms mentioned in the Private Placement Offer Cum Application Letter.
2. Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document?	Not applicable		Material deviation is not observed.	
3. Whether the means of finance for the disclosed objects of the issue has changed?			Material deviation is not observed.	
4. Is there any major deviation observed over the earlier monitoring agency reports?			The issuer has not appointed any other Monitoring Agency for these objects.	
5. Whether all Government/statutory approvals related to the object(s) have been obtained?			No Government / Statutory approvals are required for objects.	
6. Whether all arrangements pertaining to technical assistance/collaboration are in operation?			No arrangement pertaining to technical assistance / collaboration is required with reference to the object.	
7. Are there any favorable events improving the viability of these object(s)?			No favourable event is observed that may improve the viability of these objects.	
8. Are there any unfavorable events affecting the viability of the object(s)?			No unfavourable event is observed affecting the viability of these objects.	
9. Is there any other relevant information that may materially affect the decision making of the investors?			No relevant information is evident that may materially affect the decision making of the investors.	

4. Details of object(s) to be monitored:

i. Cost of object(s)

Sr. No.	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original cost (as per the Offer Document) [INR Cr.]	Revised Cost [INR Cr.]	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason of Cost revision	Proposed financing option	Particulars of firm arrangement
1	Complete acquisition of the issued, subscribed, and paid-up equity shares of Sriven Pharmachem India Private Limited.	Private Placement Offer Cum Application Letter, Certified True Copy of Extra-ordinary General Meeting, Disclosures published on Stock Exchange, Statutory Auditor's Certificate, etc.	277.17	276.87	Pursuant to the resolution dated November 06, 2025, the allotment was revised with cash consideration paid for 32,555 equity shares.	Ms. Niharika Bansal was disqualified under Regulation 159(1)(c) of the SEBI (ICDR) Regulations, 2018. Accordingly, the consideration towards acquisition of 32,555 equity shares held by Ms. Niharika Bansal was discharged in cash pursuant to the special resolution passed by the shareholders on November 06, 2025.	The acquisition of shares was approved by the shareholders through a special resolution passed on November 06, 2025. Accordingly, the consideration for acquisition of 32,555 equity shares held by Ms. Niharika Bansal was discharged in cash.	The firm arrangement for discharge of consideration towards acquisition of shares was approved by the shareholders through a special resolution passed on November 06, 2025.
Total			277.17	276.87				

Details of revision in Preferential Allotment of Equity Shares:

Category	Unit	Original	Revised
Equity Shares	No.	3,04,58,187	3,04,25,632
Price per share	INR	91.00	91.00
Total	INR Crore	277.17	276.87

ii. Progress in the object(s) –

Sr. No.	Item Heads	Source of information / certifications considered by the Monitoring Agency for the preparation of report	Amount as proposed in the Offer Document [INR Cr.]	Revised Cost as per Special Resolution [INR Cr.]	Amount utilized [INR Cr.]			Total unutilized amount [INR Cr.]	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors	
					As at beginning of the quarter	During the quarter	At the end of the quarter			Reasons for idle funds	Proposed course of action
1	Complete acquisition of the issued, subscribed, and paid-up equity shares of Sriven Pharmachem India Private Limited.	Documents provided by the Issuer including; Private Placement Offer Cum Application Letter, Certified True Copy of Extra-ordinary General Meeting, Disclosures published on Stock Exchange, Statutory Auditor's Certificate issued by M/s Sathuluri & Co., etc.	277.17	276.87	Not applicable			Not applicable	<p>The Board, at its meeting on October 09, 2025, approved the allotment of 3,04,58,187 equity shares of Astal Laboratories Limited to the shareholders of Sriven Pharmachem India Private Limited for non-cash consideration.</p> <p>The allotment was subsequently revised, pursuant to the resolution dated November 06, 2025, to 3,04,25,632 equity shares, with cash consideration paid for 32,555 shares held by Ms. Niharika Bansal, who was disqualified under Regulation 159(1)(c) of the SEBI (ICDR) Regulations, 2018.</p> <p>In-principle approval for the preferential issue of 3,04,25,632 equity shares at a price of not less than ₹91 per share was received on December 31, 2025.</p> <p>The acquisition aims to expand the Company's product portfolio and become a fully integrated pharmaceutical manufacturer.</p>	<p>The Board noted the observations of the Monitoring Agency and clarified that the revision in the proposed allotment from 3,04,58,187 equity shares to 3,04,25,632 equity shares was necessitated due to the disqualification of Ms. Niharika Bansal under Regulation 159(1)(c) of the SEBI (ICDR) Regulations, 2018. Accordingly, consideration pertaining to 32,555 shares held by her was discharged in cash in compliance with applicable regulatory provisions.</p>	<p>As a proposed course of action, the Board confirmed that:</p> <ul style="list-style-type: none"> the consideration in respect of 32,555 shares held by Ms. Niharika Bansal has been discharged in cash; the revised allotment of 3,04,25,632 equity shares has been duly approved by the shareholders; in-principle approval for the revised preferential issue has been obtained from the Stock Exchange. Allotment of 3,04,25,632

Deployment of unutilised IPO/FPO/Rights Issue Proceeds: Not applicable

Sr. No.	Type of instrument and name of the entity invested in	Amount invested [INR Cr.]	Maturity date	Earning [INR Cr.]	Return on Investment (%)	Market Value as at the end of quarter [INR Cr.]
-	-	-	-	-	-	-

iii. Delay in implementation of the object(s): Not applicable

Object(s)	Completion date		Delay [Number of days or months]	Comments of the Issuer's Board of Directors	
	As per the offer document	Actual		Reason for delay	Proposed course of action
-	-	-	-		

5. Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document: Not applicable

Sr. No.	Item Head	Amount [INR Cr.]	Source of information/certifications considered by Monitoring Agency for preparation of report	Comments of The Monitoring Agency	Comments of the Board of Directors
-	-	-	-	-	
	Total				

Disclaimer:

- a) This Report is prepared by Acuite Ratings & Research Limited (hereinafter referred to as "Monitoring Agency/MA"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors, lawyers, chartered engineers or other experts, and relies on in its reports.
- e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

About Acuite Ratings & Research

Acuite is a full-service Credit Rating Agency registered with the Securities & Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI) for Bank Loan Ratings under BASEL-II norms in the year 2012. Acuite has assigned ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Kanjurmarg, Mumbai.